ICLUSIG® expert videos

Valentín García-Gutiérrez

Servicio de Hematología
Hospital Universitario Ramón y Cajal (IRYCIS)
Madrid, Spain

Before the discovery of ICLUSIG, treatment failure in CML was devastating for patients^1–3

Valentín García-Gutiérrez Disclosures

Company/Organisation	Relationship(s)
Novartis, BMS, Incyte, Pfizer	Travel grants, research funding, advisory board

Simona Soverini

Institute of Hematology
‘L. & A. Seràgnoli’
University of Bologna
Bologna, Italy

ICLUSIG became the first and remains the only pan-inhibitor of BCR::ABL1 approved for CML in Europe, collectively suppressing all single point mutations (including T315I)^4,5

Simona Soverini Disclosures

Company/Organisation	Relationship(s)
Incyte	Consultancy

Jane Apperley

Centre for Haematology
Hammersmith Hospital
Imperial College London
London, UK

ICLUSIG has been with you since 2013, proudly demonstrating fast, deep and durable responses as seen in the long-term follow-up of the PACE study^5,6

Jane Apperley Disclosures

Company/Organisation	Relationship(s)
Incyte, Novartis, Paladin Labs	Speaker
Incyte, Novartis	Advisory boards
BMS, Incyte, Novartis, Pfizer	Research funding

Jorge Cortes

Georgia Cancer Center
Augusta, GA, USA

Thanks to the recent response-based dosing study, OPTIC, there’s now clear evidence to induce, reduce and maintain ICLUSIG to manage your patients⁷

Induce response with 45 mg orally, once daily; reduce dose to 15 mg orally, once daily, upon achievement of ≤1% BCR::ABL1; maintain response with 15 mg orally, once daily.

Jorge Cortes Disclosures

Company/Organisation	Relationship(s)
BMS, Novartis, Pfizer, Takeda, Sun Pharma, Incyte	Consultant
BMS, Novartis, Pfizer, Takeda, Sun Pharma	Research support

ICLUSIG: a decade of building patients’ futures

We’re celebrating 10 years since the initial approval of ICLUSIG in Europe!